An observational study in Obesity, sponsored by Novo Nordisk A/S. Enrolling by invitation at 18 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Novo Nordisk A/S · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 207 studies in Obesity by Novo Nordisk A/S — 48 open to participants now, 66 under way, 26 of them phase 3. Obesity · Novo Nordisk A/S.
Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 31st largest by planned enrollment of the 41 observational ones that give a count, is one of 22 that started in 2025, is one of 41 observational ones, reaches primary completion later than 28 of the 65 other live ones, and was the 159th registered.
11,536 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →48 of the 207 studies in Obesity by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in Germany
Ages 18+
Novo Nordisk A/S · Sites in Japan
Ages 18+
By country, each count listing its studies:
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
207 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 86 · Phase 2 14 · Phase 3 62 · Phase 4 4
First in 2007; this study’s year is marked. 22 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 115 across 2,158 observational studies indexed under Obesity.
Median enrollment 138 across the 166 interventional studies, 1,260 across the 41 observational. Of the 138 that completed or were terminated, 39 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 100 (49%) have results posted.
26 of the studies in Obesity by Novo Nordisk A/S that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07011667Phase 3Novo Nordisk A/SA Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term | 2027-03-01 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07745504Phase 3Novo Nordisk A/SA Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight | 2027-05-18 |
| NCT07225816Novo Nordisk A/SExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | 2026-12-13 |
Add all 26 to your calendar (.ics) → With an account.
Among the 207 studies in Obesity by Novo Nordisk A/S, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is to investigate the effectiveness and safety of Wegovy (semaglutide) in Korean patients living with obesity in routine clinical practice. The purpose of this study is to investigate the change in body weight and other clinical characteristics related to body weight in patients living with obesity. Participants will be treated with Wegovy (semaglutide) as prescribed by their doctor, in accordance with normal clinical practice. The study will last for about 52 weeks.
Participants will be treated with commercially available semaglutide. The treating physician will initiate treatment with commercially available semaglutide prior to and independently from the decision to include the participant in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be treated with commercially available semaglutide. The treating physician will initiate treatment with commercially available semaglutide prior to and independently from the decision to include the participant in the study.
Drug: Semaglutide
Semaglutide injection will be self-administered once weekly subcutaneously.
Percentage change in body weight
Percent (%)
Time frame: From baseline (week 0) to 24 weeks
Absolute change in body weight
Kilogram (kg)
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Percentage change in body weight
Percent (%)
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Achievement in body weight reduction more than or equal to (≥) 5%
Count of patients
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Achievement in body weight reduction ≥ 10%
Count of patients
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Achievement in body weight reduction ≥ 15%
Count of patients
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Achievement in body weight reduction ≥ 20%
Count of patients
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in body composition of Lean body mass
Kg
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in body composition of Total fat mass
Kg
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in body composition of Lean body mass
Percent (%)
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in body composition of Total fat mass
Percent (%)
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in Body mass index (BMI)
Kilogram per meter square (kg/m\^2)
Time frame: From baseline (week 0) up to 8, 16, 24, 32, 40, 52 weeks
Change in the proportion of patients by BMI Class I obesity (25 to 29.9 kg/m^2)
Count of patients
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in the proportion of patients by BMI Class II obesity (30 to 34.9 kg/m^2)
Count of patients
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in the proportion of patients by BMI Class III obesity (≥35 kg/m^2)
Count of patients
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in waist circumference
Centimetre (cm)
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Systolic blood pressure (SBP)
Millimetres of mercury (mmHg)
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Diastolic blood pressure (DBP)
mmHg
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Fasting plasma glucose (FPG)
Milligram per deciliter (mg/dL)
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Haemoglobin A1c (HbA1c)
Percent (%)
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Lipids: total cholesterol (TCh)
mg/dL
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Lipids: high-density lipoprotein cholesterol (HDL-C)
mg/dL
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Lipids: low-density lipoprotein cholesterol (LDL-C)
mg/dL
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Lipids: triglycerides (TG)
mg/dL
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in cardiometabolic parameters - Lipids: free fatty acid (FFA)
mg/dL
Time frame: From baseline (week 0) to 8, 16, 24, 32, 40, 52 weeks
Change in status of type two diabetes mellitus (T2DM)
Count of patients
Time frame: Baseline (week 0) to 52 weeks [or end of the study (EOS)]
Change in status of Hypertension
Count of patients
Time frame: Baseline (week 0) to 52 weeks (or EOS)
Change in status of Dyslipidemia
Count of patients
Time frame: Baseline (week 0) to 52 weeks (or EOS)
Number of treatment-emergent adverse events (TEAEs)
Count of events
Time frame: From baseline (week 0) to 52 weeks (or EOS)
Number of serious TEAEs
Count of events
Time frame: From baseline (week 0) to 52 weeks (or EOS)
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Oct 2027, 23 months after the start.
Of 45 industry-sponsored observational studies under Obesity, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's planned 23 months is close to that.
Counting every sponsor, half of 838 studies reached it within 39 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.